RUNX2 in mammary gland development and breast cancer

Journal of Cellular Physiology

Volumn 228, Issue 6, 2013, Pages 1137-1142

  Ferrari, Nicola ^a   Mcdonald, Laura ^a   Morris, Joanna S ^b   Cameron, Ewan R ^b   Blyth, Karen ^a  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CASEIN; BONE SIALOPROTEIN; CELL SURFACE MARKER; COLLAGENASE 3; METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; SCLEROSTIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2;

BONE DEVELOPMENT; BONE MARROW CELL; BREAST CANCER; BREAST CELL; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; EMBRYO DEVELOPMENT; EMBRYONAL TISSUE; EPITHELIAL MESENCHYMAL TRANSITION; HEMATOPOIETIC STEM CELL; HUMAN; MAMMARY GLAND; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; NONHUMAN; OSTEOCLAST ACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; STROMA CELL; THIRD TRIMESTER PREGNANCY; TUMOR MICROENVIRONMENT;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY GLANDS, HUMAN; NEOPLASTIC STEM CELLS; PROGNOSIS; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84874204251     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24285     Document Type: Short Survey

References (83)

1. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB. 2010. Runx2 association with progression of prostate cancer in patients: Mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-821.
2. Appleford PJ, Woollard A. 2009. RUNX genes find a niche in stem cell biology. J Cell Biochem 108:14-21.
3. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE. 2011. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Mol Cell Biol 31:4609-4622.
4. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Pina V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. 2012. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405-409.
5. Barnes GL, Javed A, Waller SM, Kamal MH, Hebert KE, Hassan MQ, Bellahcene A, Van Wijnen AJ, Young MF, Lian JB, Stein GS, Gerstenfeld LC. 2003. Osteoblast-related transcription factors Runx2 (Cbfa1/AML3) and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells. Cancer Res 63:2631-2637.
6. Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, Stein GS, Gerstenfeld LC. 2004. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res 64:4506-4513.
7. Biteau B, Hochmuth CE, Jasper H. 2011. Maintaining tissue homeostasis: Dynamic control of somatic stem cell activity. Cell Stem Cell 9:402-411.
8. Blyth K, Terry A, Mackay N, Vaillant F, Bell M, Cameron ER, Neil JC, Stewart M. 2001. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20:295-302.
9. Blyth K, Cameron ER, Neil JC. 2005. The RUNX genes: Gain or loss of function in cancer. Nat Rev Cancer 5:376-387.
10. Blyth K, Vaillant F, Hanlon L, Mackay N, Bell M, Jenkins A, Neil JC, Cameron ER. 2006. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. Cancer Res 66:2195-2201.
11. Blyth K, Slater N, Hanlon L, Bell M, Mackay N, Stewart M, Neil JC, Cameron ER. 2009. Runx1 promotes B-cell survival and lymphoma development. Blood Cells Mol Dis 43:12-19.
12. Blyth K, Vaillant F, Jenkins A, McDonald L, Pringle MA, Huser C, Stein T, Neil J, Cameron ER. 2010. Runx2 in normal tissues and cancer cells: A developing story. Blood Cells Mol Dis 45:117-123.
13. Brady G, Farrell PJ. 2009. RUNX3-mediated repression of RUNX1 in B cells. J Cell Physiol 221:283-287.
14. Braun T, Woollard A. 2009. RUNX factors in development: Lessons from invertebrate model systems. Blood Cells Mol Dis 43:43-48.
15. Cameron ER, Neil JC. 2004. The Runx genes: Lineage-specific oncogenes and tumor suppressors. Oncogene 23:4308-4314.
16. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. 2011. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: The role of SNAI2. Breast Cancer Res 13:R127.
17. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. 2012. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: In vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res 18:901-911.
18. Coffman JA. 2003. Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int 27:315-324.
19. Coffman JA. 2009. Is Runx a linchpin for developmental signaling in metazoans? J Cell Biochem 107:194-202.
20. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. 2012. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486:346-352.
21. Das K, Leong DT, Gupta A, Shen L, Putti T, Stein GS, van Wijnen AJ, Salto-Tellez M. 2009. Positive association between nuclear Runx2 and oestrogen-progesterone receptor gene expression characterises a biological subtype of breast cancer. Eur J Cancer 45:2239-2248.
22. Debnath J, Brugge JS. 2005. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5:675-688.
23. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360.
24. Enomoto H, Shiojiri S, Hoshi K, Furuichi T, Fukuyama R, Yoshida CA, Kanatani N, Nakamura R, Mizuno A, Zanma A, Yano K, Yasuda H, Higashio K, Takada K, Komori T. 2003. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. J Biol Chem 278:23971-23977.
25. Galindo M, Pratap J, Young DW, Hovhannisyan H, Im HJ, Choi JY, Lian JB, Stein JL, Stein GS, van Wijnen AJ. 2005. The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts. J Biol Chem 280:20274-20285.
26. Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo A, Perou CM, Lanari C. 2011. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Res Treat 129:49-67.
27. Gupta J, Robbins J, Jilling T, Seth P. 2011. TGFbeta-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 11:311-316.
28. Hennighausen L, Robinson GW. 2005. Information networks in the mammary gland. Nat Rev Mol Cell Biol 6:715-725.
29. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, Mueller E, Benjamin T, Spiegelman BM, Sharp PA, Hopkins N, Yaffe MB. 2005. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 309:1074-1078.
30. Inman CK, Shore P. 2003. The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684-48689.
31. Inman CK, Li N, Shore P. 2005. Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein. Mol Cell Biol 25:3182-3193.
32. Javed A, Barnes GL, Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, Stein JL, Lian JB, Stein GS. 2005. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci USA 102:1454-1459.
33. Kagoshima H, Shigesada K, Kohara Y. 2007. RUNX regulates stem cell proliferation and differentiation: Insights from studies of C. elegans. J Cell Biochem 100:1119-1130.
34. Kendrick H, Regan JL, Magnay FA, Grigoriadis A, Mitsopoulos C, Zvelebil M, Smalley MJ. 2008. Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics 9:591.
35. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B. 2008. Modulation of Runx2 activity by estrogen receptor-alpha: Implications for osteoporosis and breast cancer. Endocrinology 149:5984-5995.
36. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, Hanlon L, Cameron ER, Neil JC. 2007. Runx2 disruption promotes immortalization and confers resistance to oncogene-induced senescence in primary murine fibroblasts. Cancer Res 67:11263-11271.
37. Koehler AN. 2010. A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol 14:331-340.
38. Komori T. 2011. Signaling networks in RUNX2-dependent bone development. J Cell Biochem 112:750-755.
39. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
40. Kouros-Mehr H, Werb Z. 2006. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn 235:3404-3412.
41. Kuo YH, Zaidi SK, Gornostaeva S, Komori T, Stein GS, Castilla LH. 2009. Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice. Blood 113:3323-3332.
42. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M, Putti TC, Loh M, Ko TK, Huang C, Bhalla KN, Zhu T, Ito Y, Sukumar S. 2006. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 66:6512-6520.
43. Leong DT, Lim J, Goh X, Pratap J, Pereira BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, Voorhoeve PM, Stein GS, Salto-Tellez M, Cool SM, van Wijnen AJ. 2010. Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res 12:R89.
44. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. 2009. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE 4:e7965.
45. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, Liu Y, Himeno M, Narai S, Yamaguchi A, Komori T. 2001. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 155:157-166.
46. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, Fukuyama R, Miyazaki T, Kitaura H, Nakamura K, Fujita T, Kanatani N, Moriishi T, Yamana K, Liu W, Kawaguchi H, Komori T. 2007. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn 236:1876-1890.
47. McCarthy TL, Chang WZ, Liu Y, Centrella M. 2003. Runx2 integrates estrogen activity in osteoblasts. J Biol Chem 278:43121-43129.
48. Mendoza-Villanueva D, Zeef L, Shore P. 2011. Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFbeta-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res 13:R106.
49. Moester MJ, Papapoulos SE, Lowik CW, van Bezooijen RL. 2010. Sclerostin: Current knowledge and future perspectives. Calcif Tissue Int 87:99-107.
50. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ. 2010. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7:403-417.
51. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. 1997. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89:773-779.
52. Mundy GR. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593.
53. Nagaraja GM, Othman M, Fox BP, Alsaber R, Pellegrino CM, Zeng Y, Khanna R, Tamburini P, Swaroop A, Kandpal RP. 2006. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: Comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 25:2328-2338.
54. North TE, Stacy T, Matheny CJ, Speck NA, de Bruijn MF. 2004. Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating myeloid and lymphoid cells, but not in maturing erythroid cells. Stem Cells 22:158-168.
55. Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H. 2010. Runx2 in human breast carcinoma: Its potential roles in cancer progression. Cancer Sci 101:2670-2675.
56. Osato M. 2004. Point mutations in the RUNX1/AML1 gene: Another actor in RUNX leukemia. Oncogene 23:4284-4296.
57. Osorio KM, Lilja KC, Tumbar T. 2011. Runx1 modulates adult hair follicle stem cell emergence and maintenance from distinct embryonic skin compartments. J Cell Biol 193:235-250.
58. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. 1997. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 89:765-771.
59. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, McCauley L, Shi S, Chen S, Wang CY. 2007. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13:62-69.
60. Pensa S, Watson CJ, Poli V. 2009. Stat3 and the inflammation/acute phase response in involution and breast cancer. J Mammary Gland Biol Neoplasia 14:121-129.
61. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2005. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 25:8581-8591.
62. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL, Stein GS. 2006. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 25:589-600.
63. Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB. 2008. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68:7795-7802.
64. Pratap J, Imbalzano KM, Underwood JM, Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN, Nickerson JA, Lian JB, Stein GS. 2009. Ectopic runx2 expression in mammary epithelial cells disrupts formation of normal acini structure: Implications for breast cancer progression. Cancer Res 69:6807-6814.
65. Pratap J, Lian JB, Stein GS. 2011. Metastatic bone disease: Role of transcription factors and future targets. Bone 48:30-36.
66. Rosen JM. 2012. On murine mammary epithelial stem cells: Discovery, function, and current status. Cold Spring Harbor Perspect Biol 4:a013268.
67. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, Chen Y, Deng G, Tanaka Y, Dahiya R. 2011. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 17:5287-5298.
68. Selvamurugan N, Partridge NC. 2000. Constitutive expression and regulation of collagenase-3 in human breast cancer cells. Mol Cell Biol Res Commun 3:218-223.
69. Selvamurugan N, Kwok S, Partridge NC. 2004. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem 279:27764-27773.
70. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. 2006. Generation of a functional mammary gland from a single stem cell. Nature 439:84-88.
71. Shore P. 2005. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem 96:484-489.
72. Siegel PM, Muller WJ. 2010. Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. Oncogene 29:2753-2759.
73. Smalley MJ, Kendrick H, Sheridan JM, Regan JL, Prater MD, Lindeman GJ, Watson CJ, Visvader JE, Stingl J. 2012. Isolation of mouse mammary epithelial subpopulations: A comparison of leading methods. J Mammary Gland Biol Neoplasia 17:91-97.
74. Spender LC, Whiteman HJ, Karstegl CE, Farrell PJ. 2005. Transcriptional cross-regulation of RUNX1 by RUNX3 in human B cells. Oncogene 24:1873-1881.
75. Stewart M, Terry A, Hu M, O'Hara M, Blyth K, Baxter E, Cameron E, Onions DE, Neil JC. 1997. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): Evidence for a new myc collaborating oncogene. Proc Natl Acad Sci USA 94:8646-8651.
76. Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J, Stewart M. 1999. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene 18:7124-7134.
77. Visvader JE, Smith GH. 2011. Murine mammary epithelial stem cells: Discovery, function, and current status. Cold Spring Harb Perspect Biol 3:a004879.
78. Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Spagnoli LG, Knight RA, Candi E, Melino G. 2011. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 10:1121-1131.
79. Wang CQ, Jacob B, Nah GS, Osato M. 2010. Runx family genes, niche, and stem cell quiescence. Blood Cells Mol Dis 44:275-286.
80. Wang L, Brugge JS, Janes KA. 2011. Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 108:E803-E812.
81. Wansbury O, Mackay A, Kogata N, Mitsopoulos C, Kendrick H, Davidson K, Ruhrberg C, Reis-Filho JS, Smalley MJ, Zvelebil M, Howard BA. 2011. Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment. Breast Cancer Res 13:R79.
82. Williams C, Helguero L, Edvardsson K, Haldosen LA, Gustafsson JA. 2009. Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression. Breast Cancer Res 11:R26.
83. Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, Dong JT. 2011. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2:782-791.